SCHEMBL782190

SCHEMBL782190

Clc1ccc2nc(CNCc3ccccc3)cnc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.48
MAPT P10636 1/20 0.43
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
TYMS P04818 1/20 0.41
PDE5A O76074 2/20 0.40
CCNC P24863 1/20 0.40
CDK8 P49336 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ACHE P22303 1/20 0.39
PLA2G2A P14555 1/20 0.39
PDE10A Q9Y233 1/20 0.39
CETP P11597 1/20 0.39
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18171875 0.83 HTT (0.46) MAPTHDAC1HDAC2PDE5ACCNC
SCHEMBL780564 0.79 PDGFRB (0.61) PKMMAPTTYMSPDE5AKDM4E
SCHEMBL25373983 0.74 MEN1 (0.44) PKMALDH1A1L3MBTL1KDM4AKDM4B
SCHEMBL11280702 0.73 MEN1 (0.46) PKMMAPTKDM4EALDH1A1GAA
SCHEMBL12845761 0.73 KDM4A (0.57) PKMHDAC1CCNCCDK8ALDH1A1
SCHEMBL9700931 0.72 HRH4 (0.44) MAPTKDM4EALDH1A1PDE10APDGFRB
SCHEMBL10271340 0.72 HRH4 (0.51) MAPTKDM4EALDH1A1PDE10APDGFRB
SCHEMBL782189 0.69 SCN4A (0.41) PKM
SCHEMBL13496030 0.69 PKM (0.90) PKMMAPTCCNCCDK8L3MBTL1
SCHEMBL606264 0.69 ALDH1A1 (0.62) ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2435423-B1 SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P70S6 KINASE SENTINEL ONCOLOGY LTD (GB) 2014-10-15 EP disclosed
US-8716473-B2 Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase SENTINEL ONCOLOGY LIMITED (GB) 2014-05-06 US disclosed
US-20120071478-A1 SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE SENTINEL ONCOLOGY LIMITED (GB) 2012-03-22 US disclosed
WO-2010136755-A1 SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE SENTINEL ONCOLOGY LIMITED (GB) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071478-A1 SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE CDK1, CDK2, CDK6 PKM 524/4885MAPT 2114/4885HDAC1 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.